Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.
1 . A pharmaceutical composition comprising a fecal microbiota from a single donor subject administered with one or more Faecalibacterium species or one or more growth stimulating agents for at least one Faecalibacterium species, wherein said fecal microbiota comprises an elevated level of said at least one Faecalibacterium species relative to a control fecal microbiota from the same donor subject not administered with said one or more growth stimulating agents.
2 . The pharmaceutical composition of claim Error! Reference source not found., wherein said donor subject ingests said one or more Faecalibacterium species or one or more growth stimulating agents.
3 . The pharmaceutical composition of claim Error! Reference source not found., wherein said one or more growth stimulating agents are selected from the group consisting of apple pectin, N-acetyl glucosamine, cysteine, glutathione, riboflavin, and Flavin.
4 . The pharmaceutical composition of claim Error! Reference source not found., wherein said elevated level is selected from the group consisting of 1.5-fold or more, 2-fold or more, 2.5-fold or more, 3-fold or more, 3.5-fold or more, 4-fold or more, 5-fold or more, 10-fold or more, 50-fold or more, 100-fold or more, 1000-fold or more, and 10,000-fold or more.
5 . A pharmaceutical composition comprising a first plurality of live non-pathogenic microbes capable of inhibiting or antagonizing a Fusobacterium species and a second plurality of live non-pathogenic microbes capable of inhibiting or antagonizing a Mycobacterium species.
6 . The pharmaceutical composition of claim 5 , wherein said Fusobacterium species is selected from the group consisting of F. necrophorum, F. nucleatum, F. canifelinum, F. gonidiaformans, F. mortiferum, F. naviforme, F. necrogenes, F. russii, F. ulcerans , and F. varium
7 . The pharmaceutical composition of any one of claim 5 , wherein said Mycobacterium species is Mycobacterium avium , ssp. paratuberculosis (MAP).
8 . The pharmaceutical composition of claim 7 , wherein said first plurality of live non-pathogenic microbes comprise a Faecalibacterium species
9 . The pharmaceutical composition of claim 5 , wherein said second plurality of live non-pathogenic microbes comprise one or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, or 7 or more species selected from the anti-myco group consisting of Corynebacterium, Dietzia, Gordonia, Mycobacterium, Nocardia, Segnihparus, Skermania, Tsukamurella, Turicella, Rhodococcus , and Williamsia.
10 . The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition further comprises a fecal microbe preparation.
11 . The pharmaceutical composition of claim 10 , wherein said fecal microbe preparation comprises a donor's entire or substantially complete microbiota.
12 . The pharmaceutical composition of claim 10 , wherein said fecal microbe preparation comprises a non-selected fecal microbiota.
13 . The pharmaceutical composition of claim 10 , wherein said fecal microbe preparation lacks at least one, at least 2, at least 3, or at least 4 genera of bacteria selected from the group consisting of Acidaminococcus, Akkermansia, Alistipes, Anaerotruncus, Bacteroides, Bifidobacterium, Blautia, Butyrivibrio, Clostridium, Collinsella, Coprococcus, Corynebacterium, Dorea, Enterococcus, Escherichia, Eubacterium, Haemophilus, Holdemania, Lactobacillus, Moraxella, Parabacteroides, Prevotella, Propionibacterium, Raoultella, Roseburia, Ruminococcus, Staphylococcus, Streptococcus, Subdoligranulum , and Veillonella.
14 . A method for treating IBD in a subject in need thereof, said method comprising administering a pharmaceutically active dose of an first antibiotic or probiotic to said subject to inhibit or antagonize a Fusobacterium species.
15 . The method of claim 14 , wherein said Fusobacterium species is selected from the group consisting of F. nucleatum, F. necrophorum , and F. varium.
16 . The method of claim 14 , wherein said first probiotic comprises a Faecalibacterium species.
17 . The method of claim 14 , wherein said first probiotic comprises Faecalibacterium prausnitzii.
18 . The method of claim 14 , wherein said method further administering a pharmaceutically active dose of an second antibiotic or probiotic to said subject to inhibit or antagonize a Mycobacterium species.
19 . The method of claim 18 , wherein said Mycobacterium species is Mycobacterium avium , ssp. paratuberculosis (MAP).
20 . The method of claim 18 , wherein said probiotic comprises one or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, or 7 or more species selected from the anti-myco group consisting of Corynebacterium, Dietzia, Gordonia, Mycobacterium, Nocardia, Segnihparus, Skermania, Tsukamurella, Turicella, Rhodococcus , and Williamsia.